Monitor ATR-COSF clinical study results expected late 2026 for potential partnership catalyst. The pause of ATR-12 signals capital prioritization; watch for further financing needs given $3M market cap. Recombinant protein programs are early-stage with 36-month horizon.
Price Chart
Executive Summary
Azitra issued a CEO letter to shareholders detailing a strategic reorientation toward near-term value-creating programs, including a new cosmetic ingredient program (ATR-COSF) and recombinant protein initiatives, funded by a $10.5M March financing (with up to $21M additional from warrants). The company paused enrollment in its ATR-12 Netherton syndrome trial to conserve capital, while continuing ATR-04 enrollment and adding MD Anderson as a site.
Key Facts
- Raised $10.5M in March 2026 financing, with up to $21M additional from warrant exercise.
- New ATR-COSF recombinant filaggrin program targeting cosmetic ingredient market for fine lines/wrinkles; clinical study expected late 2026, potential partnership/commercialization in 2027.
- Paused ATR-12 Netherton syndrome trial enrollment to redirect funds to ATR-COSF.
- Added MD Anderson Cancer Center as clinical site for ATR-04 (EGFR inhibitor-associated rash) program.
- Launched recombinant protein initiatives (TEV Protease, T7 RNA Polymerase) using FHCC in-licensed technology; targeting partnership/commercialization within 36 months.
Financial Impact
No revenue or earnings reported; $10.5M raised in March with potential $21M additional from warrants; no guidance provided.
Risk Factors
- Clinical trial delays or failures for ATR-COSF and ATR-04.
- Need for additional capital beyond March financing.
- Execution risk in entering new cosmetic and recombinant protein markets.
- Dilution from warrant exercises (up to $21M).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028994 |
| Exhibit: ex99-1.htm | 0001493152-26-028994 |
| Document: 0001493152-26-028994-index-headers.html | 0001493152-26-028994 |
| Document: 0001493152-26-028994-index.html | 0001493152-26-028994 |
| Document: 0001493152-26-028994.txt | 0001493152-26-028994 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+1 | — | — |
Oct 22, 2026 3d ago | 8-K | $0.0720 | awaiting T+1 | — | — |
Oct 1, 2026 25d ago | 8-K | $0.1285 $0.1320 | ▲ +2.72% | ▲ +1.98% | — |
Aug 21, 2026 9w ago | 8-K | $0.1328 $0.1504 | ▲ +13.25% | ▲ +13.55% | — |
Aug 12, 2026 10w ago | Press Release | $0.1400 $0.1393 | ▲ +0.50% | ▲ +0.30% | — |
Jun 17, 2026 18w ago | 8-K | $0.2030 $0.1717 | ▼ −15.42% | ▼ −16.20% | — |
Jun 3, 2026 20w ago | EFFECT | $0.2240 $0.2180 | ▲ +2.68% | ▲ +3.08% | — |
May 21, 2026 22w ago | S-1 | $0.2040 $0.2100 | ▼ −2.94% | ▼ −2.36% | — |
Mar 5, 2026 33w ago | 8-K | $0.1800 $0.2030 | ▲ +12.78% | ▲ +11.93% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers